175 related articles for article (PubMed ID: 31455178)
41. Disease-Specific Derangement of Circulating Endocannabinoids and
Forte D; Fanelli F; Mezzullo M; Barone M; Corradi G; Auteri G; Bartoletti D; Martello M; Ottaviani E; Terragna C; Curti A; Pagotto U; Palandri F; Cavo M; Catani L
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403407
[TBL] [Abstract][Full Text] [Related]
42. Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms.
Benedetti E; Tavarozzi R; Morganti R; Bruno B; Bramanti E; Baratè C; Balducci S; Iovino L; Ricci F; Ricchiuto V; Buda G; Galimberti S
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32650390
[TBL] [Abstract][Full Text] [Related]
43. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
Fisher DAC; Fowles JS; Zhou A; Oh ST
Front Immunol; 2021; 12():683401. PubMed ID: 34140953
[TBL] [Abstract][Full Text] [Related]
44. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
45. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk.
Ferrer-Marín F; Arroyo AB; Bellosillo B; Cuenca EJ; Zamora L; Hernández-Rivas JM; Hernández-Boluda JC; Fernandez-Rodriguez C; Luño E; García Hernandez C; Kerguelen A; Fiallo-Suárez DV; Gómez-Casares MT; Ayala R; Vélez P; Boqué C; García-Gutierrez V; Arrizabalaga B; Estrada N; Cifuentes R; Arcas I; de Los Reyes-García AM; Besses C; Vicente V; Alvarez-Larrán A; Teruel-Montoya R; González-Conejero R; Martínez C;
Leukemia; 2020 Oct; 34(10):2648-2659. PubMed ID: 32107471
[TBL] [Abstract][Full Text] [Related]
46. Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis.
Guy A; Bidet A; Ling C; Caumont C; Boureau L; Viallard JF; Parrens M
Virchows Arch; 2021 Oct; 479(4):755-764. PubMed ID: 33934231
[TBL] [Abstract][Full Text] [Related]
47. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
[No Abstract] [Full Text] [Related]
48. The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
Longhitano L; Li Volti G; Giallongo C; Spampinato M; Barbagallo I; Di Rosa M; Romano A; Avola R; Tibullo D; Palumbo GA
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707883
[TBL] [Abstract][Full Text] [Related]
49. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
50. Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review.
Al-Mashdali AF; Aldapt MB; Rahhal A; Hailan YM; Elhakeem I; Ali EA; Rozi W; Yassin MA
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766480
[TBL] [Abstract][Full Text] [Related]
51. Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Herborg LL; Nederby L; Hasselbalch HC; Aggerholm A; Roug AS
Int J Lab Hematol; 2018 Jun; 40(3):320-325. PubMed ID: 29427319
[TBL] [Abstract][Full Text] [Related]
52. Psychological Symptoms Among Patients With BCR-ABL-Negative Myeloproliferative Neoplasms.
McFarland DC; Polizzi H; Mascarenhas J; Kremyanskaya M; Holland J; Hoffman R
J Natl Compr Canc Netw; 2016 Dec; 14(12):1563-1570. PubMed ID: 27956541
[TBL] [Abstract][Full Text] [Related]
53. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
Leuk Lymphoma; 2020 Aug; 61(8):1908-1919. PubMed ID: 32323602
[TBL] [Abstract][Full Text] [Related]
54. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
55. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
[TBL] [Abstract][Full Text] [Related]
56. CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms.
Hodeib H; Abd El Hai D; Tawfik MA; Allam AA; Selim A; Elsawy AA; Youssef A
Genes (Basel); 2022 Mar; 13(3):. PubMed ID: 35328046
[TBL] [Abstract][Full Text] [Related]
57. [The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients].
Xu J; Xu Z; Wang J; Li B; Sun X; Qin T; Zhang Y; Zhang H; Fang L; Pan L; Hu N; Qu S; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):26-9. PubMed ID: 26876249
[TBL] [Abstract][Full Text] [Related]
58. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Tefferi A; Pardanani A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Gangat N; Finke CM; Schwager S; Mullally A; Li CY; Hanson CA; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland DG; Levine RL
Leukemia; 2009 May; 23(5):905-11. PubMed ID: 19262601
[TBL] [Abstract][Full Text] [Related]
59. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.
Yan M; Geyer H; Mesa R; Atallah E; Callum J; Bartoszko J; Yee K; Maganti M; Wong F; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):e1-5. PubMed ID: 25027569
[TBL] [Abstract][Full Text] [Related]
60. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
